Status:

NOT_YET_RECRUITING

Impact of Iron Supplementation on Right Ventricular Function and Exercise Performance in Hypoxia

Lead Sponsor:

University of Colorado, Denver

Conditions:

Right Ventricular Dysfunction

Hypoxia

Eligibility:

All Genders

18-60 years

Phase:

EARLY_PHASE1

Brief Summary

The purpose of this study is to determine if taking iron supplement pills improves exercise performance in low-oxygen conditions.

Detailed Description

Hypoxia (low oxygen) causes the blood vessels in the lungs to constrict (hypoxic pulmonary vasoconstriction). This increases the pressure (afterload) the right ventricle faces as it pumps blood to the...

Eligibility Criteria

Inclusion

  • Age 18 - 60
  • For women, premenopausal status

Exclusion

  • Active cardiovascular or pulmonary disease (e.g. hypertension, coronary artery disease, cardiomyopathy, arrhythmia, valvular abnormalities, diabetes, peripheral vascular disease, tobacco use, chronic obstructive pulmonary disease, asthma, interstitial lung disease, restrictive lung disease, or pulmonary hypertension)
  • Use of cardiac- or pulmonary-related medications
  • Prior history of high altitude pulmonary edema or high altitude cerebral edema
  • Body mass index \< 18.5 or \> 30
  • Anemia
  • Iron deficiency
  • Iron supplementation (oral or intravenous) in the preceding 60 days
  • Systemic anticoagulation or aspirin use that cannot be temporarily held for the study
  • Pregnancy
  • Non-cardiopulmonary disorders that adversely influence exercise ability (e.g. arthritis or peripheral vascular disease)
  • Dedicated athletic training (defined here as spending \>9 hours per week in vigorous physical activity \[≥6 mets\])
  • Regular high-altitude exercise (defined here as engaging in vigorous physical activity \[≥1 hour at ≥6 mets\] at ≥8,000 ft for \>2 days per week over the preceding 4 weeks)
  • Residence at ≥8,000 ft for 3 or more consecutive nights in the preceding 30 days

Key Trial Info

Start Date :

March 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2026

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT05349630

Start Date

March 1 2025

End Date

May 1 2026

Last Update

December 10 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States, 80045